Literature DB >> 22268623

What is active acromegaly and which parameters do we have?

S J C M M Neggers1, N R Biermasz, A J van der Lely.   

Abstract

Disease activity of acromegaly can be measured in many ways. Growth hormone (GH) and insulin-like growth factor 1 (IGF1) concentrations are the main biochemical markers used to measure the response to treatment. Both GH and IGF1 have been associated with prognosis, in particular mortality. In this review, we discuss the available parameters to assess disease activity in acromegaly.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22268623     DOI： 10.1111/j.1365-2265.2012.04346.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 2.  Extra-hepatic Acromegaly.

Authors:  Sanne E Franck; Aart Jan van der Lely; Sebastian Neggers
Journal:  Eur Endocrinol       Date:  2013-03-15

3.  Patient-focussed outcomes in acromegaly.

Authors:  Mirtha Guitelman; Alin Abreu; Ana Laura Espinosa-de-los-Monteros; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107

4.  Soluble Klotho protein as a novel serum biomarker in patients with acromegaly.

Authors:  Anna M Dąbrowska; Jerzy S Tarach
Journal:  Arch Med Sci       Date:  2014-09-05       Impact factor: 3.318

5.  Association of pre- and postoperative αKlotho levels with long-term remission after pituitary surgery for acromegaly.

Authors:  Marian Christoph Neidert; Anna Maria Zeitlberger; Henning Leske; Oliver Tschopp; Lisa Sze; Cornelia Zwimpfer; Peter Wiesli; David Bellut; René-Ludwig Bernays; Elisabeth Jane Rushing; Christoph Schmid
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 6.  Combined treatment of somatostatin analogues with pegvisomant in acromegaly.

Authors:  S E Franck; A Muhammad; A J van der Lely; S J C M M Neggers
Journal:  Endocrine       Date:  2015-12-10       Impact factor: 3.633
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.